{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 50,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 9,
  "notes": "The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/23",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.38,
        "x": 0.6,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Superior time to onset could position SPY001 as the preferred starting therapy vs. vedolizumab",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7a7d849-4150-4272-bfb4-efea9a5fec52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.02,
        "y": 0.23
      },
      "kind": "chart",
      "text": "UC induction clinical remission rates",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb38f268-0538-45fa-acc7-e959f34e5ab6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.38,
        "x": 0.6,
        "y": 0.25
      },
      "kind": "list",
      "text": "Slow onset of vedolizumab efficacy may be explained by insufficient dosing. Clear exposure-efficacy relationship observed at Week 6: Highest quartile achieved a remarkable 37.1% remission rate. Lowest exposure quartile did not separate from placebo.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b5af530-ef03-49f6-bc01-4a44a61e8c0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.38,
        "x": 0.6,
        "y": 0.6
      },
      "kind": "list",
      "text": "FDA noted \"significant exposure-response relationship\" and recommended exploring higher doses to improve remission rates.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "acb057da-9568-4fe0-bdec-c82fd42e7c00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1. Rosario, M., et. al. (2017). 2. Vedolizumab FDA Clinical Pharmacology Review. Figure sources: Multi-MOA benchmark data from adalimumab label (TNFa), ustekinumab label (IL-12/23), mirikizumab LUCENT-1 study (IL-23), PRA023 P2b (TL1A), and vedolizumab VARSITY study (a4b7). Vedolizumab exposure-response data from Rosario, M., et. al. (2017).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7dd2a08-77bc-4051-a040-b9e8f155a603",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Vedolizumab appears underdosed in induction, opportunity for SPY001 to achieve superior time to onset",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40d0ce79-b612-4809-bc1f-466f2efce11e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "127a61d7-1372-42a7-9b71-822baeef1556",
      "evidence": "list/bullet: Slow onset of vedolizumab efficacy may be explained by insufficient dosing",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "2dc2307a-088a-469e-8da6-69e847c1cb1f",
      "evidence": "The slide uses clinical data to build a logical argument for a product's competitive advantage.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}